Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
about
Nanogels as imaging agents for modalities spanning the electromagnetic spectrum25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future PerspectivesMagnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapyBasic MR relaxation mechanisms and contrast agent designEffects of Gadolinium-Based Contrast Agents on Thyroid Hormone Receptor Action and Thyroid Hormone-Induced Cerebellar Purkinje Cell MorphogenesisBiocompatibility of ferritin-based nanoparticles as targeted MRI contrast agents.In Vitro Longitudinal Relaxivity Profile of Gd(ABE-DTTA), an Investigational Magnetic Resonance Imaging Contrast Agent.Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd³⁺ to the glycosaminoglycan heparin.Metal Chelating Crosslinkers Form Nanogels with High Chelation Stability.The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma.Redox- and hypoxia-responsive MRI contrast agents.A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicityNational Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain.Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.USPIO-Enhanced MRI Neuroimaging: A Review.A simple approach to a new T8-POSS based MRI contrast agent.Alternatives to gadolinium-based metal chelates for magnetic resonance imagingSynthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imagingMolecular MRI of liver fibrosis by a peptide-targeted contrast agent in an experimental mouse model.Activatable T₁ and T₂ magnetic resonance imaging contrast agentsType of MRI contrast, tissue gadolinium, and fibrosis.Blood Pool Contrast-enhanced Magnetic Resonance Angiography with Correlation to Digital Subtraction Angiography: A Pictorial Review.Coupling fast water exchange to slow molecular tumbling in Gd3+ chelates: why faster is not always better.PET Imaging and Biodistribution of Silicon Quantum Dots in Mice.Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo.Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release.Comprehensive evaluation of the physicochemical properties of Ln(III) complexes of aminoethyl-DO3A as pH-responsive T(1) -MRI contrast agents.Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T.Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model.Synthesis and in vivo magnetic resonance imaging evaluation of biocompatible branched copolymer nanocontrast agentsT1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA.Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonanceAn extracellular MRI polymeric contrast agent that degrades at physiological pHCompensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?Gadolinium retention in the body: what we know and what we can do.Towards An Advanced Graphene-Based Magnetic Resonance Imaging Contrast Agent: Sub-acute Toxicity and Efficacy Studies in Small Animals.The protein binding substance ibuprofen does not affect the T1 time or partition coefficient in contrast-enhanced cardiovascular magnetic resonanceA neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.Overcoming the low relaxivity of gadofosveset at high field with spin locking.Gd-encapsulated carbonaceous dots with efficient renal clearance for magnetic resonance imaging.
P2860
Q26741393-19F3772A-D2BA-47DD-851B-84A50C213406Q26774810-D4ED9B96-D840-44C9-92FD-3D2FE15B3375Q27004205-43E11404-BFCF-4515-A9CE-3ACD406D756CQ27692546-3805D61C-C770-4B1A-BD1B-3F99EDB980DBQ28828872-92FDD3A3-6E2E-450D-8659-DDA978A212AEQ30276990-8507BA80-A760-4354-8E98-DB9B9BE636CFQ30277356-7F586480-4F9A-4BEA-BA59-7D819374506DQ30583956-34019F05-0DB8-4A65-9ADD-D1B2063EF5FAQ30751363-9BEEB9B5-2669-4665-A7FE-935291981BB8Q30809060-E370558D-6425-44E3-A221-3924D39431DBQ30820031-0D5F5999-23F2-4DFD-A73D-870D45508757Q30991229-476E85E8-EB01-4431-8DCC-45C5F215E6F5Q31039888-59BBECD6-D0C7-4917-A78E-5DD48042C547Q31045014-CCD8B3D4-B97E-422F-8760-1B17116D6644Q31051172-9EB5793E-B86B-41DA-9D64-5B4EFB197C8DQ31135238-180EF3EC-F04F-467D-8C71-C3DFFC3F9F24Q33557361-132EDCDF-9407-48C3-BDA0-4437633CAC2BQ33768662-F22DEF68-EDE8-4905-A06A-B55B87639183Q33768700-199648F2-EB68-44E5-A27C-01DF568C4EE0Q33823740-65CC0205-A6D6-429A-9AA7-C4F5871186B8Q34602036-18DF24CB-9B8F-46D1-BD98-63F147EFEF54Q34779865-AF60AA3C-ACD2-4A20-86C9-F987A4324DEFQ34809764-7CB4C1EA-B32A-4EE8-96AB-A69027DC43A6Q34909815-9B5CEA35-717E-4062-96E4-64EA64FB13CEQ34974971-1F55562E-5E1A-4C27-9C5C-4BCBF9260192Q34988879-19770800-B52F-4E0C-B0F8-D6D2DB4F674BQ35109777-28593B19-C991-4B59-A0AE-510943A872CAQ36059493-36D69C28-6806-472F-AD86-8E72133C019EQ36085936-52F5FC0A-92FC-49FF-8499-06484F0642D4Q36093308-FFEA7178-B2AF-4814-9B19-244E4082ED62Q36118231-8C366387-2DA7-4580-B58E-21CFEFE865CCQ36130156-7D08026D-A702-4196-972B-7A5ED339704CQ36236679-104A80FE-580A-4A77-965A-41D2C7A043B9Q36295407-C5C5A0B2-6F44-4205-8953-CEB769398B2FQ36329191-FE241CF6-7EE7-4E35-A1C7-6F2DCF1550EEQ36340346-0B1BAF3F-00E5-4EF4-A9C2-D6DBA153A81AQ36406587-CD72D303-9500-4480-9432-4DBBDC9EC1B4Q36510352-156B37E1-E16A-4DCB-8C33-7E2FE2423C9EQ36882304-1449C4BC-9B28-4A8D-9BB5-C9F62305B49DQ36948085-D073A927-9F3B-47C7-9ED1-833B7E6C7F7E
P2860
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
@ast
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
@en
type
label
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
@ast
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
@en
prefLabel
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
@ast
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
@en
P2860
P356
P1476
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
@en
P2860
P304
P356
10.1002/JMRI.21969
P577
2009-12-01T00:00:00Z